Measles in conflict-affected northern Syria: results from an ongoing outbreak surveillance program.
Conflict
Epidemic
Infectious diseases
Measles
Surveillance
Syria
Vaccine
Vaccine-preventable disease
War
Journal
Conflict and health
ISSN: 1752-1505
Titre abrégé: Confl Health
Pays: England
ID NLM: 101286573
Informations de publication
Date de publication:
21 Dec 2021
21 Dec 2021
Historique:
received:
16
10
2020
accepted:
29
11
2021
entrez:
22
12
2021
pubmed:
23
12
2021
medline:
23
12
2021
Statut:
epublish
Résumé
The Syrian conflict has dramatically changed the public health landscape of Syria since its onset in March of 2011. Depleted resources, fractured health systems, and increased security risks have disrupted many routine services, including vaccinations, across several regions in Syria. Improving our understanding of infectious disease transmission in conflict-affected communities is imperative, particularly in the Syrian conflict. We utilize surveillance data from the Early Warning Alert and Response Network (EWARN) database managed by the Assistance Coordination Unit (ACU) to explore trends in the incidence of measles in conflict-affected northern Syria and analyze two consecutive epidemics in 2017 and 2018. We conducted a retrospective time-series analysis of the incidence of clinically suspected cases of measles using EWARN data between January 2015 and June 2019. We compared regional and temporal trends to assess differences between geographic areas and across time. Between January 2015 and June 2019, there were 30,241 clinically suspected cases of measles reported, compared to 3193 cases reported across the whole country in the decade leading up to the conflict. There were 960 regional events that met the measles outbreak threshold and significant differences in the medians of measles incidence across all years (p-value < 0.001) and in each pairwise comparison of years as well as across all geographic regions (p-value < 0.001). Although most governorates faced an elevated burden of cases in every year of the study, the measles epidemics of 2017 and 2018 in the governorates of Ar-Raqqa, Deir-Ez-Zor, and Idlib accounted for over 71% of the total suspected cases over the entire study period. The 2017 and 2018 measles epidemics were the largest since Syria eliminated the disease in 1999. The regions most affected by these outbreaks were areas of intense conflict and displacement between 2014 and 2018, including districts in Ar-Raqqa, Deir-Ez-Zor, and Idlib. The spread of measles in northern Syria serves as an indicator of low immunization coverage and limited access to care and highlights the Syrian peoples' vulnerability to infectious diseases and vaccine preventable diseases in the setting of the current conflict.
Sections du résumé
BACKGROUND
BACKGROUND
The Syrian conflict has dramatically changed the public health landscape of Syria since its onset in March of 2011. Depleted resources, fractured health systems, and increased security risks have disrupted many routine services, including vaccinations, across several regions in Syria. Improving our understanding of infectious disease transmission in conflict-affected communities is imperative, particularly in the Syrian conflict. We utilize surveillance data from the Early Warning Alert and Response Network (EWARN) database managed by the Assistance Coordination Unit (ACU) to explore trends in the incidence of measles in conflict-affected northern Syria and analyze two consecutive epidemics in 2017 and 2018.
METHODS
METHODS
We conducted a retrospective time-series analysis of the incidence of clinically suspected cases of measles using EWARN data between January 2015 and June 2019. We compared regional and temporal trends to assess differences between geographic areas and across time.
RESULTS
RESULTS
Between January 2015 and June 2019, there were 30,241 clinically suspected cases of measles reported, compared to 3193 cases reported across the whole country in the decade leading up to the conflict. There were 960 regional events that met the measles outbreak threshold and significant differences in the medians of measles incidence across all years (p-value < 0.001) and in each pairwise comparison of years as well as across all geographic regions (p-value < 0.001). Although most governorates faced an elevated burden of cases in every year of the study, the measles epidemics of 2017 and 2018 in the governorates of Ar-Raqqa, Deir-Ez-Zor, and Idlib accounted for over 71% of the total suspected cases over the entire study period.
CONCLUSIONS
CONCLUSIONS
The 2017 and 2018 measles epidemics were the largest since Syria eliminated the disease in 1999. The regions most affected by these outbreaks were areas of intense conflict and displacement between 2014 and 2018, including districts in Ar-Raqqa, Deir-Ez-Zor, and Idlib. The spread of measles in northern Syria serves as an indicator of low immunization coverage and limited access to care and highlights the Syrian peoples' vulnerability to infectious diseases and vaccine preventable diseases in the setting of the current conflict.
Identifiants
pubmed: 34933672
doi: 10.1186/s13031-021-00430-0
pii: 10.1186/s13031-021-00430-0
pmc: PMC8689574
doi:
Types de publication
Journal Article
Langues
eng
Pagination
95Informations de copyright
© 2021. The Author(s).
Références
Lancet. 2010 Jan 23;375(9711):329-40
pubmed: 20109960
J Public Health (Oxf). 2013 Jun;35(2):195-9
pubmed: 23179240
PLoS Med. 2018 Apr 24;15(4):e1002559
pubmed: 29689085
BMJ Glob Health. 2017 Sep 14;2(3):e000302
pubmed: 29225945
Soc Sci Med. 2012 Dec;75(12):2370-7
pubmed: 23040083
J Med Ethics. 2015 Mar;41(3):276-7
pubmed: 25135799
Expert Rev Anti Infect Ther. 2016 Jun;14(6):547-55
pubmed: 27063349
Lancet. 2017 Dec 2;390(10111):2516-2526
pubmed: 28314568
Int J Infect Dis. 2016 Jun;47:15-22
pubmed: 27208635
Lancet. 2017 Dec 2;390(10111):2490-2502
pubmed: 28673424
Eur J Pediatr. 2018 Mar;177(3):371-380
pubmed: 29255951
Ann Am Thorac Soc. 2016 Feb;13(2):147-55
pubmed: 26784922
Hum Vaccin Immunother. 2015;11(11):2627-36
pubmed: 26406333
PLoS Pathog. 2014 Nov 13;10(10):e1004438
pubmed: 25393545
Confl Health. 2016 Nov 30;10:27
pubmed: 27956938
Annu Rev Public Health. 2016;37:205-18
pubmed: 26989827
Vaccine. 2014 Dec 5;32(51):6880-6883
pubmed: 25444814
Vaccine. 2016 Sep 7;34(39):4649-4655
pubmed: 27527818
PLoS One. 2016 Dec 19;11(12):e0168145
pubmed: 27992470
BMJ. 2013 Dec 10;347:f7375
pubmed: 24327182
Lancet Infect Dis. 2017 Dec;17(12):e420-e428
pubmed: 28757186